Francisco Chacón-Lozsán: Cytokine Storm Is Not Just Inflammation, It Is Organ Failure in Motion
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared on LinkedIn about a recent article by Raffaele Merola et al, published in Journal of Intensive Medicine:
” ‘Cytokine storm’ is not just inflammation, it is organ failure in motion.
A new review reframes ARDS beyond lung mechanics:
- ARDS is not only a respiratory disease
- It is a systemic immune catastrophe
What really happens in ARDS?
- Dysregulated immune activation leading to excess cytokine release
- Breakdown of the alveolar – capillary barrier
- Spillover into systemic circulation
The lung becomes the source and amplifier of systemic inflammation
Why patients die is NOT hypoxemia alone
The real driver:
Multiorgan dysfunction syndrome (MODS)
Cytokines don’t stay in the lungs:
- Brain leads to BBB disruption and neuroinflammation
- Heart leads to decreased contractility and arrhythmias
- Bone marrow leads to cytopenias
- Kidney leads to AKI, microvascular ischemia
- Liver leads to coagulopathy, DIC
ARDS becomes a whole-body disease
Not all ARDS is the same
Two key phenotypes:
Hyperinflammatory
- High IL-6, IL-8, TNF
- More shock, higher mortality
- Worse ventilator outcomes
Hypoinflammatory
- Lower cytokines
- Better outcomes
Same syndrome. Different biology. Different response to therapy.
Therapy: still behind the biology
- Lung – protective ventilation leads to cornerstone
- Corticosteroids leads to evidence-supported
- Cytokine removal, biologics, MSCs leads to promising but inconsistent
The problem: we treat ARDS as one diseas
The future is precision critical care
We should move:
From:
- ‘All ARDS patients get the same protocol’
To:
- Biomarker-guided therapy
- Subphenotype – driven interventions
- Timing-based immunomodulation
Clinical takeaway
If we don’t identify who is in a cytokine storm, we will continue to dilute effective therapies in heterogeneous populations.
ARDS is not failing because treatments don’t work.
It’s failing because we treat the wrong patients, at the wrong time, with the wrong strategy.”
Title: Cytokine storm in acute respiratory distress syndrome
Authors: Raffaele Merola, Patricia R.M. Rocco, Vito Marco Ranieri, Denise Battaglini
Stay updated with Hemostasis Today.
-
Sep 8, 2026, 02:49Jared Rice: High Platelets, Low Clot Risk? – What Makes Neonatal Platelets Different in Sepsis
-
Sep 8, 2026, 02:46Rasha E.: Exploring Polycythemia Vera: Beyond the Hematocrit
-
Sep 8, 2026, 02:35Ahmet Davut Aksu: Plasminogen Supplementation Enhances Alteplase Efficacy in Systemic Embolization Model
-
Sep 7, 2026, 23:56Abdel Gaffar Mohammed: Treatment Approaches for Different Types of TMA
-
Sep 7, 2026, 18:36Richard Kollen: Preventing Deep Vein Thrombosis During Long Flights
-
Sep 7, 2026, 18:34Mahmoud Hashem: Apixaban – Doses According to the Reason for Use
-
Sep 7, 2026, 18:31Julian P. Villacastin: LAAC as a Treatment Option When Long-Term Anticoagulation Is Problematic
-
Sep 7, 2026, 18:29Geoff Stooke: How Hemophilia Led the Massie Family to the Romanovs and Ronald Reagan
-
Sep 7, 2026, 18:27Sam Mbunya: September is Sickle Cell Awareness Month